Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma
Conditions
- Metastatic Castration-resistant Prostate Cancer
- Adenocarcinoma of the Prostate
Interventions
- DRUG: Selegiline
- DRUG: Docetaxel
Sponsor
László Mangel
Collaborators